Dr. Zhang on the ARCHES Trial in Prostate Cancer
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.
Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.
The ARCHES trial is investigating enzalutamide (Xtandi) in the maintenance setting for patients with metastatic castration-sensitive disease.
It is enrolling patients with metastatic castration-sensitive prostate cancer and randomizes them to either enzalutamide or placebo. The standard of care for these patients was androgen deprivation therapy alone before the LATITUDE or CHAARTED data was published, explains Zhang.
